Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Periodontal disease is a common oral health issue that can silently worsen, causing gum inflammation, tooth loss, and reduced quality of life if not detected early. This research aims to evaluate how accurately an online self-assessment tool can identify periodontal risk among adults by comparing questionnaire results with clinical periodontal examinations. The study focuses on adults in the general population and seeks to improve early detection and preventive care for periodontal disease. Participants will complete an online questionnaire about their oral health symptoms, dental history, oral hygiene habits, and other relevant factors. They will also undergo a clinical periodontal examination during the same visit, performed by a trained clinician. The clinical exam will categorize participants into low, medium, or high periodontal risk groups, serving as the reference standard to assess the questionnaires accuracy. No treatment or preventive intervention is given as part of this observational study. During the study visit, participants will fill out the online questionnaire and receive the clinical examination. Researchers will measure how well the questionnaire-based risk categories agree with the clinical findings using diagnostic accuracy methods, including sensitivity, specificity, and agreement statistics. Minimal risks include mild discomfort or minor bleeding during the exam and privacy considerations. Participants data will be securely stored with identifiers to protect confidentiality. The study results aim to support improving the self-assessment tool for better community-level oral health prevention.
Actively Recruiting
Researchers are evaluating whether early endovascular thrombectomy EVT combined with standard anticoagulation improves outcomes compared to anticoagulation alone in adults with severe cerebral venous sinus thrombosis CVST. This multicenter, randomized, open-label trial focuses on patients aged 18 to 65 presenting within 14 days of symptom onset with imaging-confirmed CVST and markers of severity, aiming to address the lack of strong evidence for EVT in this condition, especially in the Middle East, North Africa, and South Asia regions. Participants are randomly assigned to one of two groups the intervention arm receiving EVT within 24 hours plus standard anticoagulation, and the control arm receiving anticoagulation alone. EVT techniques include mechanical thrombectomy, aspiration, or balloon-assisted methods. Anticoagulation consists of intravenous heparin or low-molecular-weight heparin followed by oral anticoagulants for 3-12 months. The study spans approximately 42 months, with 18 months for enrollment and 12 months follow-up for the last patient. Participants will undergo assessments at 30, 90, and 180 days after randomization, including clinical evaluations like the modified Rankin Scale and NIH Stroke Scale, quality of life questionnaires, cognitive testing, and imaging at 90 days. Researchers will monitor functional independence at 12 months as the primary outcome, along with secondary outcomes such as recanalization rates, mortality, clinical improvement timing, quality of life, cognitive function, and seizure frequency. Safety is overseen by an independent board with interim analyses planned throughout enrollment.
Actively Recruiting
This research evaluates a novel surgical technique called Alinassers Technique for repairing hiatal hernia by reconstructing the phrenoesophageal ligament PEL with mesh. The PEL normally attaches the esophagus to the diaphragm, allowing movement during breathing and swallowing while maintaining the esophageal hiatuss integrity. Weakness or failure of this ligament can lead to hiatal hernia and gastroesophageal reflux disease GERD symptoms. The study aims to compare this new approach with the classic surgical method to reduce recurrence and improve patient outcomes. Participants will be randomly assigned to one of two groups the intervention group receiving the new technique, which involves laparoscopic hiatal hernia repair with mesh fixed to both the esophagus and diaphragm mimicking the PEL, and the control group undergoing the standard laparoscopic repair without mesh. The surgery is performed under general anesthesia with the patient in the French position, using specific port placements and a detailed dissection and reconstruction process. Follow-up visits are scheduled at 1, 3, 6, 12, and 24 months after surgery. During the study, participants will undergo preoperative assessments including questionnaires to evaluate GERD symptoms, upper gastrointestinal endoscopy, barium meal tests, esophageal pH monitoring, and manometry. After surgery, vital signs and oral intake will be monitored daily until discharge. Follow-up visits will include clinical evaluations for symptom recurrence or complications, imaging studies, and endoscopy to assess the hernia repairs success. The primary outcome is the rate of hernia recurrence at 12 months, with secondary outcomes including complications, operative time, patient satisfaction, hospital stay, readmissions, reoperations, and symptom improvement.
Actively Recruiting
This research aims to collect long-term data on patients with generalized myasthenia gravis gMG who are prescribed Alexion complement C5 inhibition therapies, including eculizumab Soliris and ravulizumab Ultomiris. It is an observational, multinational registry designed to monitor clinical outcomes and safety over time in a real-world setting. The study is led by Alexion Pharmaceuticals, Inc. and involves multiple centers worldwide. Participants who join the registry will have their medical history and gMG treatment history reviewed retrospectively at enrollment. After joining, data will be gathered prospectively during routine clinical care visits and through patient-reported outcomes, all collected electronically. The registry maintains observation and data collection for up to five years from the day of enrollment. During the study, participants will be asked to attend routine visits where their clinical status, including the Myasthenia Gravis Activities of Daily Living MG-ADL score, will be assessed. Researchers will track changes in these scores approximately five years after enrollment to understand long-term outcomes. The study does not involve any experimental treatments but monitors patients receiving prescribed Alexion therapies as part of their usual care.
Actively Recruiting
Chronic Obstructive Pulmonary Disease COPD is a major global health issue causing high morbidity and mortality, especially in low- and middle-income countries. The disease worsens with exacerbations, accelerating lung function decline and increasing death risk. Current guidelines recommend assessing lung function, exacerbation history, and symptoms to guide treatment, including triple therapy options like BreztriTrixeo BGF for patients with moderate to severe COPD who remain symptomatic despite dual therapy. The iCHOROS study aims to gather real-world data on BGFs impact on patient outcomes and quality of life in diverse populations across Latin America, Asia, and the Middle East & Africa. BGF is a fixed-dose inhaler combining budesonide ICS, glycopyrrolate LAMA, and formoterol fumarate LABA, delivered via Aerosphere technology. This observational study follows adults aged 30 to 80 who start BGF treatment as part of routine care, with no changes to standard medical management. Patients are followed for 52 weeks or until they stop BGF. Data are collected from medical records and scheduled visits at baseline, 12, 26, and 52 weeks, tracking clinical and patient-reported outcomes such as symptom scores, exacerbations, and inhaler satisfaction. Participants provide informed consent and complete questionnaires including the COPD Assessment Test CAT and modified Medical Research Council m-MRC dyspnea scale. Researchers monitor lung function tests and record exacerbation history and treatment patterns. The main goal is to assess changes in CAT scores after 12 weeks of BGF use, with additional measures at later visits. This study offers valuable insights into how BGF performs in everyday clinical settings, helping inform better COPD treatment decisions worldwide.